Members of a patient-led consortium, whose clinical trials are led by the Royal Liverpool University Hospital, the University and 11 other partners, have won three awards for their ground-breaking work on rare disease.
DevelopAKUre were presented with the Rare Orphan Advocacy and Research (ROAR) awards at the World Orphan Drug Congress in Geneva, Switzerland.
DevelopAKUre is an international research collaboration, aiming to cure Black Bone Disease otherwise known as alkaptonuria or AKU.
The consortium received the Best European Industry-Patient Organisation Engagement award, Sobi, the speciality healthcare company which supplies the drugs, received Best Biotech Pipeline and PSR Orphan Experts, which provides logistical support at every stage of the trials, received Best Contract Research Organisation.